Physician profile
Marc John Inglese
NPI 1467698159
$988,571.82
in general payments reported to CMS, 2019-2025
42 companies · $244K in 2025
The $244K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $24K · 2021: $41K · 2022: $166K · 2023: $201K · 2024: $235K · 2025: $244K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $554K · Travel and Lodging: $90K · Food and Beverage: $19K · Consulting Fee: $16K · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $554,271.00 |
| Travel and Lodging | $90,242.01 |
| Food and Beverage | $18,533.98 |
| Consulting Fee | $16,265.00 |
| Education | $163.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619,085.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $167,976.71 | 2021-2025 | Sotyktu |
| Pfizer INC. | $70,676.80 | 2019-2025 | |
| Galderma Laboratories, L.P. | $37,124.65 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Incyte Corporation | $34,953.90 | 2021-2025 | Opzelura, Opzelura |
| Amgen INC. | $27,083.79 | 2019-2025 | Otezla, Otezla |
| Celgene Corporation | $16,504.88 | 2019 | |
| Aclaris Therapeutics, INC. | $6,666.14 | 2019 | |
| Ucb, INC. | $1,375.34 | 2019-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $1,369.52 | 2020-2025 | |
| Lilly USA, LLC | $835.11 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $669.47 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $652.28 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $548.48 | 2019-2025 | |
| Leo Pharma INC. | $399.91 | 2019-2025 | Adbry, Anzupgo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $393.68 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $387.77 | 2019-2025 | Ilumya |
| Organogenesis INC. | $244.95 | 2020-2024 | |
| Janssen Scientific Affairs, LLC | $213.69 | 2022-2025 | Tremfya |
| Convatec INC. | $193.63 | 2023 | |
| Dermavant Sciences, INC. | $189.46 | 2023 | Vtama |
| Biofrontera INC. | $176.04 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $150.22 | 2019-2025 | Cabtreo |
| Vyne Pharmaceuticals INC. | $132.21 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Mayne Pharma Commercial LLC | $82.11 | 2019-2024 | |
| Genentech, INC. | $50.00 | 2023 | Xolair |
| Almirall LLC | $41.65 | 2019-2024 | Klisyri |
| Dermira, INC. | $33.09 | 2021 | |
| Verrica Pharmaceuticals INC. | $32.35 | 2023-2024 | Ycanth |
| Merck Sharp & Dohme LLC | $30.77 | 2019 | |
| Nabriva Therapeutics, Plc | $27.75 | 2021 | |
| Journey Medical Corporation | $25.16 | 2025 | |
| Chiesi USA, INC. | $22.19 | 2024 | Filsuvez |
| Mimedx Group, INC. | $20.47 | 2024 | |
| Kerecis Limited | $16.45 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Genentech USA, INC. | $14.87 | 2023 | Erivedge |
| Paratek Pharmaceuticals, INC. | $14.58 | 2025 | Nuzyra |
| Cgg Medical INC | $14.51 | 2024 | |
| Tactile Systems Technology INC | $14.41 | 2025 | Nimbl, Flexitouch Plus |
| Smith+Nephew, INC. | $14.35 | 2023 | Grafix Pl, Oasis |
| Strata Skin Sciences, INC. | $12.92 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Inglese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.